Additionally, in the MARQUEE trial for patients with advanced non-small cell lung cancer, an exploratory analysis found that patients with tumor that were at least 2+ positive for MET by IHC in more than 50 % of tumor cell experienced longer PFS and OS with combined MET-EGFR inhibition while in patients with MET-low tumors, tivantinib did not improve OS compared to placebo [23]. The gene discussed is MET; the disease is non-small cell lung carcinoma.